Oragenics Inc (OGEN.A)
8 Dec 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2011||Independent Chairman of the Board|
|57||2016||President, Chief Executive Officer, Director|
|58||2016||Chief Financial Officer, Treasurer, Secretary|
- BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis
- BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017
- BRIEF-Oragenics, Koski Family Limited partnership enters into amendment to June 30, 2016 unsecured promissory note
- BRIEF-Oragenics Inc files for stock shelf of upto $30 mln
- BRIEF-Oragenics announces receipt of payment in connection with sale of consumer probiotic biz